Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care

LONDON, October 13 /PRNewswire/ — Systagenix Wound Management has
announced the formation of a new global Medical Advisory Board, consisting of
a group of multi-disciplinary and highly respected wound care clinicians and
practitioners from North America and Europe, which will be led by
Systagenix’s newly appointed Medical Director, Dr Robert Snyder.

Representing major specialist organisations and thought leaders in the
wound care field, the Systagenix Medical Advisory Board will meet at specific
intervals to provide feedback, input and guidance on company clinical and
commercial strategies and their implementation. The group represents a broad
section of the wound care clinical community with multi-disciplinary
backgrounds, including academic and health economic experts, practicing
surgeons, and nurse specialists. As well as advising Systagenix regarding
their existing portfolio, they will focus on new and emerging technologies as
well as future clinical trends within wound care. They will also advise on
other critical issues, such as health economics and reimbursement in order to
help Systagenix meet the changing needs of the global wound care market.

In addition to clinical and new product development, working with Dr
Snyder, the Systagenix Medical Advisory Board will also focus on education,
including new pathways to help reach and communicate with fellow healthcare
professionals on the best and most up-to-date wound care practices.

Systagenix was formed by a management buyout of the Johnson & Johnson
Professional Wound Care business which had a 75 year heritage. Systagenix has
very clear objectives to become the world’s strongest and most admired wound
care company. The new Medical Advisory Board is designed to help the company
meet those objectives by better understanding the needs of the clinician and
their patients.

Systagenix’s CEO, Steve Atkinson comments: “Education, innovation and
forward thinking are crucial in the constantly changing and evolving wound
care field. We are delighted to welcome such a prestigious panel of experts
under the renowned guidance of Dr Snyder, all of whom will help us define and
refine our thinking for future clinical, educational and technological
developments.”

Dr Snyder adds: “With such a varied and experienced panel of experts, we
are bound to create new and exciting opportunities to forge ahead with
innovation which is specifically aimed at meeting clinician and patient needs
around the world. I am delighted that the Systagenix Medical Advisory Board
has been formed and I look forward to working with the group as we seek to
pioneer new ideas and techniques in wound care across a number of key areas”.

Notes to Editors:

Members of the Systagenix Clinical Advisory Board are:

Chair: Dr. Robert Snyder, DPM, CWS: Medical Director, Systagenix;
Diplomat, American Board of Podiatric Surgery; Fellow, American College of
Food & Ankle Surgery; Certified Wound Specialist; Medical Director, Wound
Healing Centre, University Hospital, Tamarac, Florida; Clinical Professor
(Adjunct), Temple University College of Podiatric Medicine; Diplomat,
American Academy of Wound Management; serves on the board of directors,
Association for the Advancement of Wound Care

Professor David G. Armstrong, DPM, PhD: Professor of Surgery (with
Tenure), University of Arizona; co-founded the Southern Arizona Limb Salvage
Alliance; founder and co-chair of the International Diabetic Food Conference

Professor Dr. Med. Matthias Augustin: Professor for Health Economics &
QoL Research Group, Department of Dermatology, University Clinics of Hamburg,
Germany

Mona M. Baharestani, PhD, ANP, CWOCN, CWS: Associate Professor &
Secretary for the Advancement of Wound Care, Center for Nursing Research,
East Tennessee State University, USA; Faculty Professor, Oxford University
Wound Healing Summer School, UK

Laura Bolton, PhD: Adjunct Associate Professor of the Department of
Surgery, Bioengineering Section, New Jersey, USA; member of Editorial Boards
of Wound Repair and Regeneration, Ostomy/Wound Management, Advances in Skin &
Wound Care & WOUNDS publications; co-chairs the Association for the
Advancement of Wound Care Guideline Department

Pr. Frank Duteille, MD: Head of Department of Plastic Reconstructive and
Esthetic Surgery, University Hospital, Nantes, France

Dieter Mayer, MD: Vascular Surgeon, EBSQ-VASC, FMH; Senior Consultant of
Vascular Surgery & Head of Wound Care, Zurich University Hospital, Switzerland

Zena Moore, PhD, MSc, FFNMRCSI, PG Dip, RGN: Lecturer in Wound Healing &
Tissue Repair & Research Methodology, Faculty of Nursing & Midwifery, Royal
College of Surgeons in Ireland; Current President of European Wound
Management Association and chair of the education committee

Prof. Marco Romanelli, MD, PhD: Consultant Dermatologist, Department of
Dermatology, University of Pisa, Italy; Director Wound Healing Research Unit,
University of Pisa; leads a research group actively involved in clinical,
laboratory and educational activities

Dr Thomas E. Serena, MD, FACS, FACHM, FAPWCA: Founder & Medical Director
of Pennsylvania North Centers for Advanced Wound Care, USA; founder of the
NewBridge Medical Research Corporation and emeritus member of the Board of
Director of the Wound Healing Society

Prof. Gary Sibbald, BSc, MD, FRCPC (Med) (Derm), ABIM, DABD, MEd:
Professor of Public Health Sciences and Medicine, University of Toronto;
Director of medical education for Women’s College Hospital and Chair of the
faculty of Medical Education Committee; Board member and President of the
Canadian Association of Continuing Health Education, University of Toronto,
Canada

Dot Weir, RN, CWON, CWS: Director of Wound Care for Osceola Regional
Medical Center, Florida, USA; held posts of Treasurer & President of
Association for Advancement of Wound Care

Thomas Wild, MD: Department of Surgery, University of Vienna, Austria;
President Elect of Austrian Wound Association

Systagenix Portfolio Details

Professional Advanced Wound Care Products:

ACTISORB(R) Activated Charcoal Dressing with Silver – helps to manage
infection through its unique mode of action that traps and kills bacteria and
eliminates malodors. The first commercialized silver dressing available at
the time of its launch in 1980. The safety and efficacy of ACTISORB(R)
Dressings is now supported with published clinical evidence in over 13,000
patients.

ADAPTIC(R) Non-Adhering Dressing – helps to protect regenerating tissue
and minimizes patient pain and trauma during dressing changes.

INADINE(R) PVP-I Non-Adherent Dressing – a topical wound dressing
impregnated with an ointment containing 10% povidone iodine is indicated for
the management of ulcerative wounds and may also be used for the prevention
of infection in minor burns and minor traumatic skin loss injuries

NU-GEL(R) Hydrogel with Alginate – a transparent hydro active amorphous
gel containing sodium alginate creates a moist wound-healing environment,
which assists with natural autolytic debridement and desloughing of wounds.

PROMOGRAN(R) Matrix Dressing – a unique, clinically proven combination of
collagen and oxidized regenerated cellulose (“ORC”); facilitates tissue
granulation through modulation of the wound environment.

PROMOGRAN PRISMA(TM) Balancing Matrix Dressing – combines collagen and
ORC with an optimal level of silver; helps restore the normal wound-healing
environment by reducing bacterial levels without causing harm to host cells.

REGRANEX(R) (becaplermin) Gel 0.01% – a gel containing recombinant human
platelet derived growth factor; the first and only growth factor approved for
clinical use in the U.S. and Europe to heal and close lower extremity
diabetic neuropathic ulcers.

SILVERCEL(R) Anti-microbial Alginate Dressing – provides a controlled,
balanced and sustained release of silver that helps manage infection and
exudates while offering superior dressing tensile strength for easy, intact
removal.

TIELLE(R) Hydropolymer Dressings – a broad range of foam dressings
handling different levels of exudates to reduce wound maceration and leakage
while optimizing cost effectiveness through increased dressing wear time.

Professional General Wound Care Products:

TOPPER(R) Drain Swab and TOPPER(R) Non-Woven Fabric Swab – a unique
rayon/polyester, non-woven sponge that provides improved strength,
absorbency, and scrubbing texture compared to traditional gauze.

RELEASE(R) Low-Adherent Dressing – utilizes a unique perforated film
design that directs exudates away from the wound; minimizes discomfort and
tissue damage during dressing changes.

REGAL(R) Filmated Non-Woven Swab – a multi-layer absorbent swab covered
with a film of viscose fibers to disperse exudates and to provide enhanced
absorption capability.

About Systagenix

Systagenix Wound Management was formed by a management buyout of the
Johnson & Johnson Professional Wound Care business which had a 75 year
heritage. Systagenix aims to become the world’s strongest and most admired
wound care company. The business has the history and knowledge, and a new,
dynamic, energetic and highly informed management team to take it to the next
level in the UK and across the globe.

Systagenix manufactures in excess of 30 million wound dressings a month.
These are used to treat patients in hospitals, nursing homes and also in
their own homes in over 50 countries. Some of the products are used to treat
acute wounds in surgery and accidents, where they are used to protect against
infection and encourage the wound to heal naturally, while other products,
and this is where Systagenix’s reputation has been forged and revered, is in
advanced wound care, where the business has created products that actively
promote healing in some of the most challenging wounds that result from
chronic conditions such as diabetes, obesity and vascular disease. It is in
these situations that Systagenix’s products are used to save patients from
limb amputation.

For more information:

Contact Susan Leigh or Gilllian Waddell on +44-(0)207-498-8211

susan@fuelrefuel.com or Gillian@fuelrefuel.com

SOURCE Systagenix